Are stable MS patients who stop their disease-modifying therapy (DMT) at increased risk for relapses and disability progression compared to patients who continue on DMTs? A propensity-score matched analysis of the MSBase registrants

I Kister, Tim Spelman, Raed Alroughani, Jeannette Lechner-Scott, P Duquette, F Grand'Maison, Mark Slee, A Lugaresi, M Barnett, P Grammond, Gerardo Iuliano, R Hupperts, M Trojano, H Butzkueven, MSBase Study Group

    Research output: Contribution to journalMeeting Abstractpeer-review

    Original languageEnglish
    Pages (from-to)17-18
    Number of pages2
    JournalMultiple Sclerosis
    Volume21
    Issue numberSupp: 11
    DOIs
    Publication statusPublished - Sept 2015
    Event31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis - Barcelona, Spain
    Duration: 7 Oct 201510 Oct 2015
    Conference number: 31

    Cite this